Form 4: Cytek Biosciences CFO Reports Stock Transaction
Insider Transaction (Form 4)
William D. Mccombe, Chief Financial Officer of Cytek Biosciences, Inc., reported multiple transactions in common stock on August 18, 2026.
Summary
- Option exercise/conversion: acquired 6,320 Common Stock on August 18, 2026; holds 117,497 after (Direct).
- Tax/exercise-price withholding: disposed of 2,111 Common Stock at $4.67 ($9,858) on August 18, 2026; holds 115,386 after (Direct).
- Option exercise/conversion: acquired 13,051 Common Stock on August 18, 2026; holds 128,437 after (Direct).
- Tax/exercise-price withholding: disposed of 4,392 Common Stock at $4.67 ($20,511) on August 18, 2026; holds 124,045 after (Direct).
- Option exercise/conversion: acquired 16,049 Common Stock on August 18, 2026; holds 140,094 after (Direct).
- Tax/exercise-price withholding: disposed of 5,401 Common Stock at $4.67 ($25,223) on August 18, 2026; holds 134,693 after (Direct).
- Option exercise/conversion: disposed of 6,320 Restricted Stock Units on August 18, 2026; holds 44,249 after (Direct).
- Option exercise/conversion: disposed of 13,051 Restricted Stock Units on August 18, 2026; holds 134,862 after (Direct).
- Option exercise/conversion: disposed of 16,049 Restricted Stock Units on August 18, 2026; holds 230,042 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
William D. Mccombe — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Option exercise/conversion | Common Stock | 6,320 | — | — | 117,497 |
| 2026-08-18 | Tax/exercise-price withholding | Common Stock | 2,111 | $5 | $9.9K | 115,386 |
| 2026-08-18 | Option exercise/conversion | Common Stock | 13,051 | — | — | 128,437 |
| 2026-08-18 | Tax/exercise-price withholding | Common Stock | 4,392 | $5 | $20.5K | 124,045 |
| 2026-08-18 | Option exercise/conversion | Common Stock | 16,049 | — | — | 140,094 |
| 2026-08-18 | Tax/exercise-price withholding | Common Stock | 5,401 | $5 | $25.2K | 134,693 |
| 2026-08-18 | Option exercise/conversion | Restricted Stock Units | 6,320 | — | — | 44,249 |
| 2026-08-18 | Option exercise/conversion | Restricted Stock Units | 13,051 | — | — | 134,862 |
| 2026-08-18 | Option exercise/conversion | Restricted Stock Units | 16,049 | — | — | 230,042 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Option exercise/conversion (6,320 shares) |
| 2026-08-18 | Tax/exercise-price withholding (2,111 shares) |
| 2026-08-18 | Option exercise/conversion (13,051 shares) |
| 2026-08-18 | Tax/exercise-price withholding (4,392 shares) |
| 2026-08-18 | Option exercise/conversion (16,049 shares) |
| 2026-08-18 | Tax/exercise-price withholding (5,401 shares) |
| 2026-08-18 | Option exercise/conversion (6,320 shares) |
| 2026-08-18 | Option exercise/conversion (13,051 shares) |
| 2026-08-18 | Option exercise/conversion (16,049 shares) |
Keywords
insider transaction, Form 4, CTKB, Cytek Biosciences, Inc., neutral, William D. Mccombe
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.